Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma
October 30, 2024 08:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrstu níu mánuði ársins 2024 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. nóvember nk. Þá mun Alvotech halda...
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
October 30, 2024 08:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of...
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
October 30, 2024 08:30 ET
|
Alvotech
REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
October 25, 2024 08:00 ET
|
Alvotech
REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024
October 25, 2024 08:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) fundar með erlendum fjárfestum á heilbrigðisráðstefnu fjárfestingabankans Jefferies, í London dagana 19.- 20. nóvember n.k. Stjórnendur Alvotech munu einnig flytja kynningu á...
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
October 25, 2024 08:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 22, 2024 07:00 ET
|
Alvotech
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved...
Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi
October 22, 2024 07:00 ET
|
Alvotech
Aukið markaðsleyfi er veitt fyrir Selarsdi í Bandaríkjunum til meðferðar við Crohns- sjúkdómnum og sáraristilbólgu, sem eru þrálátir bólgusjúkdómar í meltingarvegiMatvæla- og lyfjaeftirlit...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
October 22, 2024 07:00 ET
|
Alvotech
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
October 10, 2024 05:01 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency...